Sareum Holdings plc

LSE SAR.L

Sareum Holdings plc Market Capitalization on January 14, 2025: USD 35.09 M

Sareum Holdings plc Market Capitalization is USD 35.09 M on January 14, 2025, a -61.55% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Sareum Holdings plc 52-week high Market Capitalization is USD 91.28 M on January 15, 2024, which is 160.11% above the current Market Capitalization.
Sareum Holdings plc 52-week low Market Capitalization is USD 16.16 M on April 02, 2024, which is -53.95% below the current Market Capitalization.
Sareum Holdings plc average Market Capitalization for the last 52 weeks is USD 48.65 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

LSE: SAR.L

Sareum Holdings plc

CEO	Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D.
IPO Date	Oct. 11, 2004
Location	United Kingdom
Headquarters	Langford Arch
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

Key trends

Past 5 years